Search
Disease prediction for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis using methylome profiling: the EPIC4ND study – EPIC4ND
Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) are progressive neurodegenerative disorders (NDs) showing growing prevalence in industrialized, aging populations. Despite all three disorders having a genetic basis, it is becoming increasingly evident that
A premotor disease signature for ALS – premodiALS
Amyotrophic lateral sclerosis (ALS) is the most frequent motoneuron disease with a devastating prognosis. Even today, it takes on average 12 months from the onset of motor symptoms to establish the diagnosis of ALS and approximately half of the patients are initially misdiagnosed. Although several
Presymptomatic synaptic disorders in Alzheimer’s disease – PreSSAD
It is widely accepted that synaptic alteration/loss is the strongest predictor of cognitive decline in Alzheimer’s disease. However, this has mainly been based on histopathological studies in post-mortem brains which do not capture dynamic events that precede the observed synapse loss and in parti
COgNiTive propagation in pRodrOmaL Parkinson’s disease – CONTROL-PD
Parkinson’s disease (PD) has a long prodromal phase, in which latent cerebral changes can manifest itself as prodromal symptoms, for example idiopathic REM-sleep behavioural disorder (RBD), hyposmia, and cognitive-affective symptoms (e.g. anxiety and depression). Increasing evidence suggests that
Risk factors and markers for early detection of Alzheimer’s Disease: focus on early-life adversity, inflammation and lipid mediators – SOLID
Finding suitable and easily measurable early biomarkers for neurodegeneration and cognitive dysfunction represents the next frontier for prevention and early intervention strategies in diseases like Alzheimer’s Disease (AD). Our collective work in preclinical models has demonstrated that early-lif
Leveraging medical records to identify patients at risk of neurodegenerative disease – LeMeReND
Neurodegenerative diseases represent one of the main public health issues in our western societies and one of the greatest challenges in drug development. Prevention policies have become essential to address these issues: primary prevention to prevent disease onset by acting on actionable risk fac
MIcroglial early Neuroinflamatory Dysfunction in Fontotemporal Dementia and Amyotrophic Lateral Sclerosis due to C9orf72 repeat Expansions – MIND FACE
Expansion of a (G4C2) repeat in C9orf72 is the most common autosomal dominant cause of frontotemporal dementia and amyotrophic lateral sclerosis (ALS). Strong arguments indicate that immune-system related dysfunction may contribute as disease modifier to the large phenotypic variation in onset age